Literature DB >> 8449602

int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc.

J A Henry1, C Hennessy, D L Levett, T W Lennard, B R Westley, F E May.   

Abstract

Amplification of the int-2 oncogene was measured in a series of breast tumours and related to amplification of the c-myc and c-erbB-2 oncogenes, histopathological features and relapse-free and overall survival. int-2 was amplified in 11%, c-myc in 20% and c-erbB-2 in 27% of the tumours assessed. int-2 amplification was associated with large tumour size (p < 0.05) and reduced relapse-free (p < 0.05) and overall (p < 0.0005) survival. c-myc amplification was associated with poor tumour differentiation (p < 0.05) but had no association with prognosis. c-erbB-2 amplification was associated with low levels of expression of oestrogen receptor mRNA (p < 0.05), poor tumour differentiation (p < 0.05) and shortened relapse-free (p < 0.0001) and overall survival (p < 0.0001). This is the first report of an association between amplification of the int-2 oncogene in breast tumours and a significantly increased risk of death from breast cancer, and suggests that int-2 may be useful for identifying breast-cancer patients having a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449602     DOI: 10.1002/ijc.2910530512

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Cyclin D1 amplification and expression in human breast carcinoma: correlation with histological prognostic markers and oestrogen receptor expression.

Authors:  S D Worsley; B A Jennings; K H Khalil; M Mole; A C Girling
Journal:  Clin Mol Pathol       Date:  1996-02

Review 2.  Cyclins and breast cancer.

Authors:  E A Musgrove; R Hui; K J Sweeney; C K Watts; R L Sutherland
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

3.  Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.

Authors:  A Forus; H K Høifødt; G E Overli; O Myklebost; O Fodstad
Journal:  Mol Pathol       Date:  1999-04

4.  Regulation of the functional interaction between cyclin D1 and the estrogen receptor.

Authors:  J Lamb; M H Ladha; C McMahon; R L Sutherland; M E Ewen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

5.  No difference in CCND1 gene expression between breast cancer patients with and without lymph node metastasis in a Southern Brazilian sample.

Authors:  L B L Maia; F S C Breginski; T C S Cavalcanti; R L R de Souza; V M S Roxo; E M S F Ribeiro
Journal:  Clin Exp Med       Date:  2015-09-26       Impact factor: 3.984

Review 6.  Chromosome 11q13 markers and D-type cyclins in breast cancer.

Authors:  G Peters; V Fantl; R Smith; S Brookes; C Dickson
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.

Authors:  I Bièche; M Olivi; C Noguès; M Vidaud; R Lidereau
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

8.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Authors:  R Michalides; P Hageman; H van Tinteren; L Houben; E Wientjens; R Klompmaker; J Peterse
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

9.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

Authors:  Claus M Schlotter; Ulf Vogt; Ulrich Bosse; Berthold Mersch; Katja Wassmann
Journal:  Breast Cancer Res       Date:  2003-01-13       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.